Can bacitracin and colistin be used together?

Rarely. Bacitracin is topical only; colistin is systemic. In some surgical or wound care scenarios, bacitracin might be applied topically while a patient receives colistin systemically for a separate infection, but this is not a synergistic combination—they're simply treating different sites or infections in parallel.

Is colistin safe for routine infections?

No. Colistin's nephrotoxicity and neurotoxicity profiles make it suitable only for serious, life-threatening infections caused by multidrug-resistant gram-negatives when other options are exhausted. For routine infections, safer alternatives should be prioritised.

Why isn't bacitracin approved in Europe?

The European Medicines Agency (EMA) has stricter regulatory pathways for topical antibiotics and concerns about promoting antibiotic stewardship. Bacitracin exists in some European markets under older national approvals, but no unified EMA marketing authorisation has been granted in recent years.

Can bacitracin treat systemic infections?

No. Bacitracin is poorly absorbed systemically and is formulated only for topical use. For systemic infections, you need a systemically available antibiotic like colistin, vancomycin, or a fluoroquinolone, depending on the organism and resistance profile.

Is colistin resistance a real problem?

Yes. [Plasmid-mediated resistance genes (mcr genes) have emerged globally, spreading colistin resistance among gram-negative bacteria](https://pubmed.ncbi.nlm.nih.gov/27207519). This is a major concern for future infectious disease management and emphasises the need for colistin stewardship and new drug development.

Bacitracin vs Colistin: Mechanism, Use Cases & Differences

Bacitracin and colistin are both FDA-approved antibiotics, but they work in fundamentally different ways and are used for different clinical scenarios. Bacitracin is a topical antibiotic that disrupts bacterial cell wall formation, while colistin is a systemic antibiotic reserved for serious gram-negative infections resistant to other drugs. Understanding the differences—mechanism, regulatory status, and clinical application—helps clarify when each is the right choice.

What is Bacitracin?

Bacitracin is a cyclic peptide antibiotic produced by the bacterium Bacillus subtilis. It was discovered in 1945 and approved by the FDA as a topical agent for minor cuts, scrapes, and wound care. The compound works by inhibiting bacterial cell wall synthesis—specifically, it blocks the dephosphorylation of lipid carrier molecules essential for peptidoglycan formation, which is the rigid backbone of gram-positive and some gram-negative bacterial cell walls.

Bacitracin is formulated as an ointment, powder, or ophthalmic preparation. It's available over-the-counter in many countries and is a staple of first-aid kits. The antibiotic has a narrow spectrum: it's most effective against gram-positive bacteria like Staphylococcus aureus and Streptococcus pyogenes, and some gram-negative organisms, but it does not reliably cover Pseudomonas aeruginosa or other difficult gram-negatives.

Clinical Evidence for Bacitracin

Over 40 clinical trials have evaluated bacitracin across topical wound care, ophthalmology, and prevention of surgical site infections. The evidence base is robust: a landmark systematic review confirmed bacitracin's efficacy in preventing wound infections when applied topically. Most trials are pragmatic, comparing bacitracin-based ointments to placebo or other topical agents. Adverse effects are minimal; bacitracin is poorly absorbed systemically, and local allergic reactions are rare.

Regulatory Status: Bacitracin

United States: FDA-approved as a topical antibiotic (OTC and prescription formulations)
European Union: Not authorised by the EMA as a standalone product; some formulations exist in limited markets
Canada: Approved by Health Canada for topical use

What is Colistin?

Colistin (polymyxin E) is a polypeptide antibiotic discovered in the 1940s. Unlike bacitracin, colistin is a systemic antibiotic—it can be given intravenously or inhaled—and it's reserved for last-resort treatment of multidrug-resistant (MDR) gram-negative infections. Colistin works by disrupting the outer membrane of gram-negative bacteria, causing cell leakage and death.

Colistin has a broad gram-negative spectrum and is particularly valuable against Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae that are resistant to carbapenems and fluoroquinolones. However, colistin carries a real risk of nephrotoxicity (kidney damage) and neurotoxicity at therapeutic doses, which is why it's only used when other options have failed.

Clinical Evidence for Colistin

Over 119 clinical trials have examined colistin across critical care, cystic fibrosis, and infectious disease settings. A major systematic review and meta-analysis of colistin monotherapy versus combination regimens for carbapenem-resistant gram-negative infections found that combination therapy may improve outcomes in ventilator-associated pneumonia. The evidence supports colistin's role as a salvage therapy, particularly when administered as part of a combination regimen.

Adverse events are notable: nephrotoxicity occurs in 10–70% of patients depending on renal function and dosing strategy, and neurotoxicity (tremor, confusion, paresthesias) has been documented in 5–10% of cases.

Regulatory Status: Colistin

United States: FDA-approved for intravenous and inhaled formulations (approved 1959, re-evaluated for critical care use in recent years)
European Union: EMA-authorised for systemic and inhaled use
Canada: Health Canada approved for intravenous and inhaled formulations

Key Differences: Bacitracin vs Colistin

1. Route of Administration

Bacitracin is topical only—applied to skin, wounds, or eyes. Colistin is systemic: intravenous infusion or aerosol inhalation for deep lung infections. This fundamental difference determines their use cases entirely.

2. Spectrum of Activity

Bacitracin covers gram-positive bacteria and some gram-negatives, but it's unreliable against challenging organisms like Pseudomonas. Colistin has superior gram-negative coverage and is specifically designed for MDR gram-negative pathogens, making it essential for serious systemic infections resistant to multiple drug classes.

3. Toxicity Profile

Bacitracin is remarkably safe—topical absorption is minimal, and serious adverse effects are rare. Colistin carries real toxicity risks: dose-dependent nephrotoxicity and neurotoxicity are documented in large trial cohorts. This is why colistin is only used when benefits clearly outweigh risks.

4. Clinical Context

Bacitracin is appropriate for:

Minor wound care and infection prevention
Ophthalmic infections (e.g., conjunctivitis prevention in newborns)
Topical surgical prophylaxis
Home first-aid use

Colistin is reserved for:

Nosocomial infections caused by carbapenem-resistant gram-negatives
Ventilator-associated pneumonia with MDR pathogens
Cystic fibrosis patients with Pseudomonas respiratory colonisation
Acute infections in critically ill patients when other options are exhausted

5. Resistance Considerations

Bacterial resistance to bacitracin exists but is uncommon in clinical practice, partly because it's used primarily for superficial infections where systemic resistance mechanisms are less relevant. Resistance to colistin, historically rare, has emerged in recent years—particularly plasmid-mediated mcr genes—creating concern about colistin's long-term utility as a last-resort agent.

Mechanism of Action: A Closer Look

Both are peptide antibiotics, but they work via different mechanisms:

Bacitracin: Inhibits the enzyme dephosphorylase, preventing recycling of lipid carrier molecules in the peptidoglycan synthesis pathway. This starves the bacterial cell wall of building blocks.

Colistin: Inserts itself into the outer membrane of gram-negative bacteria (which bacitracin cannot access well), disrupting membrane integrity and causing leakage of cellular contents. This is why colistin is so effective against gram-negatives and why it works systemically.

Which Should You Use?

The choice is usually clear from clinical context:

For minor wounds, cuts, or eye infections: Bacitracin is the standard topical choice. It's safe, effective, and available OTC.
For serious systemic MDR gram-negative infections: Colistin is a critical tool, but it requires careful monitoring of renal and neurological function.

If you're managing an infection in a clinical setting, consult the latest antibiotic stewardship guidelines and local resistance patterns. Bacitracin and colistin rarely compete—they serve different niches in antibiotic therapy.

Related Compounds

For a deeper understanding of topical and systemic peptide antibiotics, explore:

Polymyxin B — a close structural relative of colistin with similar gram-negative coverage
Vancomycin — a glycopeptide often used alongside or instead of colistin for resistant infections
Daptomycin — a cyclic lipopeptide with a different mechanism for difficult gram-positives

Understanding antibiotic resistance and peptide antibiotics will also help contextualise when each compound is appropriate.

Bacitracin vs Colistin: A Detailed Comparison